The Immunomodulatory Effects of Oral Administration of Azithromycin and Echinacea spp in Pasteurella multocida Vaccinated Rats

Document Type : Original Article

Authors

Pharmacology Dept, Faculty of Vet. Med., Zagazig University

Abstract

The present study was carried out to investigate the effects of Azithromycin (Zisrocin®) and Echinacea spp < /em> (Mulone®), alone and their combination on the immune response of the rat as a laboratory model. In this experiment, 40 male rats were employed and divided into four equal groups each of ten. The first group (control group) received 0.5 ml saline. The second group received Mulone® (5 mg/100 gm), the third group received Zisrocin (4.5 mg/100 gm) and the fourth group received Mulone® (5 mg/100 gm) with Zisrocin® (4.5 mg/100 gm) as oral gavage daily for 5 days, respectively. All groups were vaccinated with Pasteurella  multocida (4 × 109/ml CFU of P.multocida) on the 6th day of the experiment then blood samples were collected from all groups at Zero, 1st , 2nd and 3rd day post vaccination. Whole blood and serum samples were collected and used for phagocytic activity, nitric oxide (NO) production and lysozyme activity. The results showed that the combination of Zisrocin and Mulone, synergistically, provoked a significant increase in the phagocytic and lysozyme activities than Zisrocin treated, Mulone treated and control groups, while induced a significant decrease in serum NO level than Zisrocin and control group. Our results concluded that the simultaneous use of Zisrocin and Mulone improved the immune and the anti-inflammatory responses in vaccinated rats.
The present study was carried out to investigate the effects of Azithromycin (Zisrocin®) and Echinacea spp < /em> (Mulone®), alone and their combination on the immune response of the rat as a laboratory model. In this experiment, 40 male rats were employed and divided into four equal groups each of ten. The first group (control group) received 0.5 ml saline. The second group received Mulone® (5 mg/100 gm), the third group received Zisrocin (4.5 mg/100 gm) and the fourth group received Mulone® (5 mg/100 gm) with Zisrocin® (4.5 mg/100 gm) as oral gavage daily for 5 days, respectively. All groups were vaccinated with Pasteurella  multocida (4 × 109/ml CFU of P.multocida) on the 6th day of the experiment then blood samples were collected from all groups at Zero, 1st , 2nd and 3rd day post vaccination. Whole blood and serum samples were collected and used for phagocytic activity, nitric oxide (NO) production and lysozyme activity. The results showed that the combination of Zisrocin and Mulone, synergistically, provoked a significant increase in the phagocytic and lysozyme activities than Zisrocin treated, Mulone treated and control groups, while induced a significant decrease in serum NO level than Zisrocin and control group. Our results concluded that the simultaneous use of Zisrocin and Mulone improved the immune and the anti-inflammatory responses in vaccinated rats.

Main Subjects